ACTION TO CONTROL CARDIOVASCULAR RISK IN DIABETES (ACCORD)

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 2型糖尿病患者死于心血管疾病（CVD）的比率比具有类似人口统计学特征的非糖尿病人群高2至4倍。 他们还经历非致命性心肌梗死和中风的发生率增加。 随着肥胖在美国的日益流行，预计与2型糖尿病相关的CVD在未来几十年将成为比现在更大的公共卫生挑战。 事件发生率的预期增加将伴随着痛苦和资源利用的增加。 尽管这一健康问题在北美人群中很重要，但缺乏关于强化控制糖尿病和其他CVD危险因素对糖尿病患者CVD事件发生率的影响的确切数据。 控制糖尿病心血管风险行动（雅阁）试验的总体目标是通过测试2型糖尿病的三种补充药物治疗策略来应对这一挑战，以增加降低这种疾病中仍然非常高的主要CVD发病率和死亡率的选择。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Patients with type 2 diabetes mellitus die of cardiovascular disease (CVD) at rates two to four times higher than non-diabetic populations of similar demographic characteristics. They also experience increased rates of nonfatal myocardial infarction and stroke. With the growing prevalence of obesity in the United States, CVD associated with type 2 diabetes is expected to become an even greater public health challenge in the coming decades than it is now. Expected increases in event rates will be associated with a concomitant rise in suffering and resource utilization. Despite the importance of this health problem in the North American population, there is a lack of definitive data on the effects of intensive control of glycemia and other CVD risk factors on CVD event rates in diabetic patients. The overall goal of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial is to address this challenge by testing three complementary medical treatment strategies for type 2 diabetes to enhance the options for reducing the still very high rate of major CVD morbidity and mortality in this disease.